Kalbe Farma KLBF IJ -Buy- Transforming the brand
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Consumer Durables JW SH SC 2.9K 2nd May, 2025
1Q25 result review: Strong start
AMRT started the year with a solid set of results, with 1Q25 revenue and NPAT reaching a low-teens percentage y-y growth despite a tougher macro backdrop. GPM increased both q-q and y-y, despite the typically lower GPM during the Lebaran season, attributable to the company's initiative to cut promotions by half and being more selective in handing out promotions. The improvement in GPM during 1Q25 is particularly important, in our view, as it indicates that the company has learned from its strategic missteps in 4Q24 and is now able to turn things around. Opex as a percentage of sales improved q-q and remained flat y-y, despite pressure from higher minimum wage increases and expenses related to new openings last year. We expect new opening-related opex as a percentage of sales to continue declining in subsequent quarters.
What to see beyond 1Q25
While challenges may persist in the coming quarters – particularly due to softer consumer purchasing power – we remain confident that the defensive nature of AMRT’s business model will enable it to outperform its peers. Historically, AMRT has maintained stable mid-single-digit same-store sales growth (SSSG) even during the most difficult macroeconomic conditions (Fig. 2). At the same time, the company has consistently generated a steady increase in free cash flow over the past five years (Fig. 3). Our forecast assumes 2024-2027F revenue / net profit CAGRs of 10.5%/15% – making AMRT one of the few Indonesian large-cap stocks capable of delivering double-digit growth on both top and bottom lines.
Maintain Buy on AMRT with TP of IDR2,350
Our TP is pegged on a 27.6x 2025F P/E target, equal to its five-year average P/E. Balancing growth and profitability will be a key strategic focus for the company amid the current macroeconomic headwinds. We view the company’s ability to recover from its strategic missteps in 4Q24 as a positive catalyst for the stock. Key downside risks include prolonged weakness in consumer purchasing power, as well as the potential for significant foreign capital outflows, given that the local-to-foreign investor ratio in AMRT stands at approximately 1:8/9. Currently, the stock trades at 25x 2025F P/E.
| AMRT IJ | QoQ | YoY | 3M25/ | 3M25/ | |||
| Profit and loss statement (IDRbn) | 1Q24 | 4Q24 | 1Q25 | (%) | (%) | Verdhana | Consensus |
| Revenue | 29,326 | 30,010 | 32,773 | 9.2 | 11.8 | 25.3 | 25.3 |
| COGS | (22,937) | (23,513) | (25,600) | 8.9 | 11.6 | ||
| Gross profit | 6,389 | 6,497 | 7,172 | 10.4 | 12.3 | ||
| EBIT (incl. fee-based) | 1,051 | 909 | 1,163 | 27.9 | 10.7 | 27.4 | 26.9 |
| Other income/(expenses) | |||||||
| Fee based income | 175 | 185 | 178 | (3.9) | 1.8 | ||
| Net financing income/(expense) | (0) | (2) | 9 | n.a. | n.a. | ||
| Others | 101 | 48 | 92 | 91.4 | (9.3) | ||
| Pre-tax profit | 1,152 | 955 | 1,265 | 32.4 | 9.7 | ||
| Net profit | 890 | 749 | 975 | 30.1 | 9.5 | 27.6 | 26.6 |
| Gross margin (%) | 21.8 | 21.6 | 21.9 | ||||
| EBIT margin (%) | 3.6 | 3.0 | 3.5 | ||||
| Pre-tax margin (%) | 3.9 | 3.2 | 3.9 | ||||
| Net margin (%) | 3.0 | 2.5 | 3.0 | ||||
| Mar-24 | Dec-24 | Mar-25 | |||||
| Cash and equivalents | 3,603 | 4,845 | 7,011 | ||||
| Total assets | 40,378 | 38,798 | 46,449 | ||||
| Total liabilities | 23,845 | 21,102 | 27,767 | ||||
| Interest bearing liabilities | 150 | 0 | 0 | ||||
| Equity | 15,271 | 16,378 | 17,331 | ||||
| ROA (%) | 8.8 | 7.7 | 8.4 | ||||
| ROE (%) | 23.3 | 18.3 | 22.5 | ||||
| Gearing (%) | 1.0 | 0.0 | 0.0 | ||||
| Net gearing (%) | n.c. | n.c. | n.c. |
INVESTMENT RATINGS
A rating of ‘Buy’, indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of ‘Neutral’, indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of ‘Reduce’, indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of ‘Suspended’, indicates that the rating, target price, and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies. Securities and/or companies that are labelled as ‘Not Rated’ or ‘No Rating’ are not in regular research coverage. Benchmark is Indonesia Composite Index (‘IDX Composite’). A ‘Target Price’, if discussed, indicates the analyst’s forecast for the share price with a 12-month time horizon, reflecting in part of the analyst’s estimates for the company’s earnings, and may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market in general.
GENERAL DISCLOSURE/DISCLAIMER
This report is prepared by PT Verdhana Sekuritas Indonesia (“PTVSI”) a securities company registered in Indonesia, supervised by Indonesia Financial Services Authority (OJK) and a member of the Indonesia Stock Exchange (IDX).
This report is intended for client of PTVSI only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of PTVSI.
The research set out in this report is based on information obtained from sources believed to be reliable, but PTVSI do not make any representation or warranty as to its accuracy, completeness or correctness. The information in this report is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company (or companies) referred to in this report. Any information, valuations, opinions, estimates, forecasts, ratings or targets herein constitutes a judgment as of the date of this report is published, and there is no assurance that future results or events will be consistent.
This report is not to be construed as an offer or a solicitation of an offer to buy or sell any securities or financial products. PTVSI and its associates, its directors, and/or its employees may from time to time have interests in the securities mentioned in this report or it may or will engage in any securities transaction or other capital market services for the company (companies) mentioned herein.
ANALYST CERTIFICATION
The research analyst primarily responsible for the content of this report and certifies that the views about the companies including their securities expressed in this report accurately reflect his/her personal views. The analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.
RESTRICTIONS ON DISTRIBUTION
By accepting this report, the recipient hereof represents and warrants that you are entitled to receive such report in accordance with the restrictions and agrees to be bound by the limitations contained herein. Neither this report nor any copy hereof may be distributed except in compliance with applicable Indonesian capital market laws and regulations.
| Rating Remains | Buy |
| Target price Remains | IDR 2,350 |
| Closing price 30 April 2025 | IDR 2,160 |
Jody Wijaya (jody.wijaya@verdhana.id)
Sandy Ham (sandy.ham@verdhana.id)
Samuel Christian (samuel.christian@verdhana.id)
saya
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Based on our survey of distributors and wholesalers, MYOR's domestic sales may have grown
As mentioned in our previous reports, Indonesia local FMCG companies have
Our analysis of FMCG and retail sales data of companies we track across Indonesia suggests that Sulawesi,
AMRT has consistently outperformed its FMCG peers in terms of sales growth over the past decade
Indonesia is a young nation (110mn population are below 40yrs, based on BPS) as well as social media-savvy (th